Microdissection genotyping of gliomas: Therapeutic and prognostic considerations

Modern Pathology

Volumn 17, Issue 11, 2004, Pages 1346-1358

  Mohan, Deepak ^a,c   Finkelstein, Sydney D ^a   Swalsky, Patricia A ^a   Sasatomi, Eizaburo ^a   Wiley, Clayton ^a   Hamilton, Ronald L ^a   Lieberman, Frank ^b   Couce, Marta E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

1p 19q; Fractional allelic loss; Glioma; Loss of heterozygosity; Microdissection genotyping; Molecular anatomic pathology

Indexed keywords

DNA;

ALLELISM; ARTICLE; CHROMOSOME 10Q; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 9P; CONTROLLED STUDY; GENOTYPE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MICRODISSECTION; MOLECULAR BIOLOGY; MULTIGENE FAMILY; MUTATION; PATHOLOGICAL ANATOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TISSUE FIXATION; TREATMENT OUTCOME;

BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENOTYPE; GLIOMA; HUMANS; MICRODISSECTION; PROGNOSIS;

EID: 8144223994     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800194     Document Type: Article

References (55)

1. Kleihues P, Cavenee WK, (eds). WHO Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. IARC Press: Lyon, 2000.
2. Schiffer D. Classification and biology of astrocytic gliomas. Forum (Genova). 1998;8:244-255.
3. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61, 215-225; 226-229.
4. Pollack IF, Biegel J, Yates A, et al. Risk assignment in childhood brain tumors: the emerging role of molecular and biologic classification. Curr Oncol Rep 2002;4:114-122.
5. Caskey LS, Fuller GN, Bruner JM, et al. Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol 2000;15:971-981.
6. Collins VP. Progression as exemplified by human astrocytic tumors. Semin Cancer Biol 1999;9:267-276.
7. Zagzag D, Friedlander DR, Margolis B, et al. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 2000;33:49-55.
8. Henson JW. Early genetic events in the formation of astrocytomas. Curr Opin Neurol 2000;13:613-617.
9. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-129.
10. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-1333.
11. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000;60:6617-6622.
12. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-6891.
13. Nishizaki T, Ozaki S, Harada K, et al. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 1998;21:340-346.
14. Paunu N, Sallinen SL, Karhu R, et al. Chromosome imbalances in familial gliomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000;29:339-346.
15. Rohlff C. Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis 2000;21:1227-1234.
16. Rutka JT, Taylor M, Mainprize T, et al. Molecular biology and neurosurgery in the third millennium. Neurosurgery 2000;46:1034-1051.
17. Rutka JT, Akiyama Y, Lee SP, et al. Alterations of the p53 and pRB pathways in human astrocytoma. Brain Tumor Pathol 2000;17:65-70.
18. Nagane M, Lin H, Cavenee WK, et al Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 2001; 162(Suppl):S17-S21.
19. Ivanchuk SM, Mondal S, Dirks PB, et al. The INK4A/ ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J Neurooncol 2001;51: 219-229.
20. Finkelstein SD, Przygodzki R, Swalsky PA. Microdissection-based p53 genotyping: concepts for molecular testing. Mol Diagn 1998;3:179-191.
21. Pollack IF, Finkelstein SD, Woods J, et al, Children's Cancer Group. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002; 346:420-427.
22. Chozick BS, Weicker ME, Pezzullo JC, et al. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 1994;73:406-415.
23. Pollack IF, Hamilton RL, Finkelstein SD, et al. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997;57:304-309.
24. Pollack IF, Finkelstein SD, Burnham J, et al, Children's Cancer Group. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 2001;61: 7404-7407.
25. Finkelstein SD, Hasegawa T, Colby T, et al. 11q13 allelic imbalance discriminates: pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice. Am J Pathol 1999; 155:633-640.
26. Safatle-Ribeiro AV, Ribeiro Jr U, Sakai P, et al. Integrated p53 histopathologic/genetic analysis of premalignant lesions of the esophagus. Cancer Detect Prev 2000;24:13-23.
27. Cong WM, Bakker A, Swalsky PA, et al. Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study. J Cancer Res Clin Oncol 2001;127:187-192.
28. Raja S, Finkelstein SD, Baksh FK, et al. Correlation between dysplasia and mutations of six tumor suppressor genes in Barrett's esophagus. Ann Thorac Surg 2001;72:1130-1135.
29. Fan CY, Liu KL, Huang HY, et al. Frequent allelic imbalance and loss of protein expression of the DNA repair gene hOGG1 in head and neck squamous cell carcinoma. Lab Invest 2001;81:1429-1438.
30. Rolston R, Sasatomi E, Hunt J, et al. Distinguishing de novo second cancer formation from tumor recurrence: mutational fingerprinting by microdissection genotyping. J Mol Diagn 2001;3:129-132.
31. Rubin MA. Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Pathol 2001;195: 80-86.
32. Mariani L, McDonough WS, Hoelzinger DB, et al. Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res 2001;61:4190-4196.
33. Mariani L, Beaudry C, McDonough WS, et al. Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 2001;7:2480-2489.
34. Smit ML, Giesendorf BA, Heil SG, et al. Automated extraction and amplification of DNA from whole blood using a robotic workstation and an integrated thermocycler. Biotechnol Appl Biochem 2000;32:121-125.
35. Weiler J, Gausepohl H, Hauser N, et al. Hybridisation based DNA screening on peptide nucleic acid (PNA) oligomer arrays. Nucleic Acids Res 1997;25: 2792-2799.
36. Belgrader P, Devaney JM, Del Rio SA, et al. Automated polymerase chain reaction product sample preparation for capillary electrophoresis analysis. J Chromatogr B Biomed Appl 1996;683:109-114.
37. Perry JR, Louis DN, Cairncross JG. Current treatment of oligodendrogliomas. Arch Neurol 1999;56:434-436.
38. Burton E, Prados M. New chemotherapy options for the treatment of malignant gliomas. Curr Opin Oncol 1999;11:157-161.
39. Perry JR. Oligodendrogliomas: clinical and genetic correlations. Curr Opin Neurol 2001;14:705-710.
40. Croteau D, Mikkelsen T, Rempel SA, et al. New innovations and developments for glioma treatment. Clin Neurosurg 2001;48:60-81.
41. Bigner SH, Rasheed BK, Wiltshire R, et al. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro-oncol. 1999;1:52-60.
42. Biegel JA. Cytogenetic and molecular genetics of childhood brain tumors. Neuro-oncol 1999;1:139-151.
43. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
44. Paleologos NA, Cairncross JG. Treatment of oligodendroglioma: an update. Neuro-oncol 1999;1:61-68.
45. Sehgal A. Molecular changes during the genesis of human gliomas. Semin Surg Oncol 1998;14:3-12.
46. Rasheed BK, Wiltshire RN, Bigner SH, et al. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999;11:162-167.
47. Goussia AC, Agnantis NJ, Rao JS, et al. Cytogenetic and molecular abnormalities in astrocytic gliomas (Review). Oncol Rep 2000;7:401-412.
48. Weiss WA. Genetics of brain tumors. Curr Opin Pediatr 2000;12:543-548.
49. Takeshima H, Sawamura Y, Gilbert MR, et al. Application of advances in molecular biology to the treatment of brain tumors. Curr Oncol Rep 2000;2:425-433.
50. Hill JR, Kuriyama N, Kuriyama H, et al. Molecular genetics of brain tumors. Arch Neurol 1999;56: 439-441.
51. Fueyo J, Gomez-Manzano C, Yung WK, et al. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 1998;51:1250-1255.
52. Nozaki M, Tada M, Kobayashi H, et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncol. 1999;1: 124-137.
53. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-1792.
54. Sung T, Miller DC, Hayes RL, et al. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000;10:249-259.
55. Darling JL, Warr TJ. Biology and genetics of malignant brain tumours. Curr Opin Neurol 1998;11:619-625.